Vanguard Portfolio Management (KRYS) Discloses 5.05% Holding in Krystal Biotech
Rhea-AI Filing Summary
Krystal Biotech Inc ownership filing: Vanguard Portfolio Management reports beneficial ownership of 1,479,111 shares of Common Stock, representing 5.05% of the class. The filing states Vanguard has sole dispositive power over 1,479,111 shares and sole voting power for 22,384 shares.
The disclosure attributes holdings to Vanguard Portfolio Management and identified affiliates and notes these positions include shares held for Vanguard funds and managed accounts.
Positive
- None.
Negative
- None.
Insights
Vanguard reports a >5% stake, signalling notable passive ownership.
Vanguard Portfolio Management discloses beneficial ownership of 1,479,111 shares or 5.05% of Krystal Biotech common stock, with sole dispositive power over the full amount and limited sole voting power on 22,384 shares. The filing attributes holdings to Vanguard and affiliates, including funds and managed accounts.
Because this is a Schedule 13G disclosure, the position is presented as passive under the form's standards. Subsequent filings would show changes; current cash‑flow treatment or trading intentions are not stated in the excerpt.
Key Figures
Key Terms
Schedule 13G regulatory
Beneficially owned financial
Dispositive power regulatory
Sole voting power regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.